Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries

Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study

(2014) Mark Jit et al.   Lancet Global Health

Global health 2035: a world converging within a generation

(2013) Dean T Jamison et al.   LANCET

Applying an equity lens in the Decade of Vaccines

(2013) Lara Brearley et al.   VACCINE

Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects

(2013) Jannah Wigle et al.   VACCINE

Overcoming perceptions of financial barriers to rotavirus vaccine introduction in Asia

(2013) E Anthony S Nelson et al.   Human Vaccines & Immunotherapeutics

Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries

(2012) Rohan Deogaonkar et al.   BMC PUBLIC HEALTH

Worldwide burden of cervical cancer in 2008

(2011) M. Arbyn et al.   ANNALS OF ONCOLOGY

Pricing of new vaccines

(2011) Bruce Y. Lee et al.   Human vaccines & immunotherapeutics

A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries

(2011) Suerie Moon et al.   Globalization and Health

Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India

(2010) Swathi Padmanabhan et al.   NATURE BIOTECHNOLOGY

Estimated research and development costs of rotavirus vaccines

(2009) Donald W. Light et al.   VACCINE

Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006–January 2008

(2008) Anna Koulova et al.   VACCINE